Supriya Lifescience Q4 Revenue Surges 50% YoY; FY26 PAT up 11.3%
Supriya Lifescience Ltd. announced strong financial results for Q4 FY26 and the full year FY26. For Q4 FY26, revenue surged 50.2% year-over-year to ₹276.53 crore, with Profit After Tax (PAT) at ₹74.23 crore. For the full fiscal year FY26, revenue from operations grew 18.9% YoY to ₹827.87 crore, and PAT increased 11.3% YoY to ₹209.12 crore. The anesthetic segment was the primary growth driver, contributing 54% of total revenues in FY26. Europe remained the largest market, and export contribution was strong at approximately 82% of FY26 revenues. The company also commercialized its Liquid Anesthetic product, improved capacity utilization to 74%, and strengthened its manufacturing and R&D infrastructure.
Key Highlights
- Q4 FY26 Revenue surged 50.2% YoY to ₹276.53 crore; PAT was ₹74.23 crore.
- FY26 Revenue grew 18.9% YoY to ₹827.87 crore; PAT rose 11.3% to ₹209.12 crore.
- Anesthetic segment drove FY26 growth, contributing 54% of total revenues.
- Export contribution remained strong at 82% of FY26 revenues, with Europe as the largest market.
- Capacity utilization improved to 74%; new products commercialized and facilities expanded.
Price Impact
More from SUPRIYA